Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)
SEK 35.5
(-2.74%)
SEK 35.5
(-2.74%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 351.33 Million SEK | 0.49% |
| 2022 | 349.61 Million SEK | -14.41% |
| 2021 | 408.47 Million SEK | -9.29% |
| 2020 | 450.31 Million SEK | -13.11% |
| 2019 | 518.27 Million SEK | -8.01% |
| 2018 | 563.37 Million SEK | 221.88% |
| 2017 | 175.02 Million SEK | 58.96% |
| 2016 | 110.1 Million SEK | 33.4% |
| 2015 | 82.54 Million SEK | 467.81% |
| 2014 | 14.53 Million SEK | 1027.91% |
| 2013 | 1.28 Million SEK | 2576.57% |
| 2012 | 48.15 Thousand SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 348.87 Million SEK | -0.7% |
| 2024 Q2 | 296.44 Million SEK | -15.03% |
| 2023 Q3 | 386.71 Million SEK | 21.84% |
| 2023 FY | 351.33 Million SEK | 0.49% |
| 2023 Q4 | 351.33 Million SEK | -9.15% |
| 2023 Q1 | 333.69 Million SEK | -4.55% |
| 2023 Q2 | 317.39 Million SEK | -4.89% |
| 2022 Q1 | 409.96 Million SEK | 0.36% |
| 2022 Q2 | 400 Million SEK | -2.43% |
| 2022 Q4 | 349.61 Million SEK | -11.79% |
| 2022 Q3 | 396.36 Million SEK | -0.91% |
| 2022 FY | 349.61 Million SEK | -14.41% |
| 2021 Q4 | 408.47 Million SEK | -3.08% |
| 2021 Q1 | 451.13 Million SEK | 0.18% |
| 2021 Q2 | 429.41 Million SEK | -4.82% |
| 2021 FY | 408.47 Million SEK | -9.29% |
| 2021 Q3 | 421.45 Million SEK | -1.85% |
| 2020 Q1 | 523.16 Million SEK | 0.94% |
| 2020 FY | 450.31 Million SEK | -13.11% |
| 2020 Q2 | 492.62 Million SEK | -5.84% |
| 2020 Q3 | 480.3 Million SEK | -2.5% |
| 2020 Q4 | 450.31 Million SEK | -6.24% |
| 2019 Q3 | 545.34 Million SEK | -1.74% |
| 2019 FY | 518.27 Million SEK | -8.01% |
| 2019 Q4 | 518.27 Million SEK | -4.96% |
| 2019 Q2 | 554.97 Million SEK | -1.08% |
| 2019 Q1 | 561.03 Million SEK | -0.41% |
| 2018 FY | 563.37 Million SEK | 221.88% |
| 2018 Q2 | 600.42 Million SEK | 0.52% |
| 2018 Q4 | 563.37 Million SEK | -4.48% |
| 2018 Q3 | 589.82 Million SEK | -1.77% |
| 2018 Q1 | 597.31 Million SEK | 241.27% |
| 2017 Q3 | 83 Million SEK | -10.0% |
| 2017 FY | 175.02 Million SEK | 58.96% |
| 2017 Q1 | 100.92 Million SEK | -8.34% |
| 2017 Q2 | 92.22 Million SEK | -8.62% |
| 2017 Q4 | 175.02 Million SEK | 110.86% |
| 2016 Q4 | 110.1 Million SEK | 0.0% |
| 2016 FY | 110.1 Million SEK | 33.4% |
| 2016 Q2 | 133.12 Million SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2015 Q3 | 82.54 Million SEK | 0.0% |
| 2015 FY | 82.54 Million SEK | 467.81% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | 82.54 Million SEK | 0.0% |
| 2014 FY | 14.53 Million SEK | 1027.91% |
| 2013 FY | 1.28 Million SEK | 2576.57% |
| 2012 FY | 48.15 Thousand SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| NextCell Pharma AB | 81.28 Million SEK | -332.209% |
| Biovica International AB (publ) | 131.4 Million SEK | -167.361% |
| Abliva AB (publ) | 87.49 Million SEK | -301.529% |
| Active Biotech AB (publ) | 44 Million SEK | -698.486% |
| Aptahem AB (publ) | 63.02 Million SEK | -457.452% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -196.61% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 74.908% |
| BioArctic AB (publ) | 1.18 Billion SEK | 70.379% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -465.282% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 81.514% |
| Cantargia AB (publ) | 223.71 Million SEK | -57.047% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -2262.862% |
| CombiGene AB (publ) | 120.61 Million SEK | -191.293% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 53.784% |
| Fluicell AB (publ) | 9.34 Million SEK | -3661.606% |
| Genovis AB (publ.) | 288.85 Million SEK | -21.629% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 65.489% |
| Mendus AB (publ) | 755.95 Million SEK | 53.524% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 72.081% |
| LIDDS AB (publ) | 17.65 Million SEK | -1889.997% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -737.327% |
| Saniona AB (publ) | 64.14 Million SEK | -447.736% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -563.082% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -463.243% |
| Xintela AB (publ) | 18.39 Million SEK | -1809.943% |
| Amniotics AB (publ) | 26.08 Million SEK | -1246.83% |
| Corline Biomedical AB | 100.1 Million SEK | -250.965% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -1064.397% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -98.358% |
| Intervacc AB (publ) | 259.61 Million SEK | -35.331% |
| Kancera AB (publ) | 65.64 Million SEK | -435.219% |
| Lipum AB (publ) | 12.11 Million SEK | -2801.189% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -945.575% |
| Nanologica AB (publ) | 77.42 Million SEK | -353.75% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 29.202% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 46.239% |
| AcouSort AB (publ) | 34.51 Million SEK | -917.976% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -61.877% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -346.467% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | -26.041% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -1653.076% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 54.09% |
| Simris Alg AB (publ) | 174.55 Million SEK | -101.278% |
| Ziccum AB (publ) | 14.97 Million SEK | -2246.607% |
| SynAct Pharma AB | 228.01 Million SEK | -54.081% |
| OncoZenge AB (publ) | 20.34 Million SEK | -1627.306% |
| Camurus AB (publ) | 1.9 Billion SEK | 81.585% |
| 2cureX AB (publ) | 16.62 Million SEK | -2013.287% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -5681.372% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -149.887% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -1518.836% |
| I-Tech AB | 152.44 Million SEK | -130.469% |
| Cyxone AB (publ) | 43.65 Million SEK | -704.797% |
| Biosergen AB | 7.2 Million SEK | -4778.961% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -1212.76% |
| Alzinova AB (publ) | 123.18 Million SEK | -185.199% |
| Oncopeptides AB (publ) | 238.37 Million SEK | -47.385% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -312.233% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -4055.34% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -303.498% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -1132.405% |